Lean Beef Consumption and Insulin Sensitivity in Men and Women With Risk Factors for Diabetes

Metabolic Syndrome Clinical Trial

Official title:

A Randomized, Controlled-Feeding, Crossover Trial to Assess the Effects of Increasing Lean Beef Consumption Within a Healthy Dietary Pattern on Insulin Sensitivity in Men and Women With Risk Factors for Diabetes Mellitus.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03202680
• Other study ID #: MB-1606
• Status: Completed
• Phase: N/A
• Start date: July 6, 2017
• Est. completion date: July 16, 2019

Study information

• Verified date: July 2019
• Source: Midwest Center for Metabolic and Cardiovascular Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this trial is to compare the effects of a healthy, lean beef diet and an average American, United States Department of Agriculture (USDA) style diet, that is low in saturated fatty acids (SFA), on insulin sensitivity in men and women with risk factors for diabetes mellitus.

Description:

This is a randomized, controlled, crossover study that includes two screening visits, one baseline visit, two 28-d test periods and an end-of-washout visit. A 2-week washout period will separate the two treatments. Subjects will be screened to identify metabolic syndrome and/or prediabetes at the screening visits. Eligible subjects will be randomly assigned to a test sequence (USDA/lean beef or lean beef/USDA diets) and the appropriate calorie menu within each test diet, which will be determined based on each subject's calculated energy needs for weight maintenance. Study foods will be dispensed, and subjects will be instructed to consume all of the foods in their entirety for the duration of each 28-d test period, and avoid consuming any additional food or drink items that has not been provided to them. Compliance will be assessed through a Food Deviation Log where subjects will record any non-study food/beverages consumed, and any portions of the study foods not consumed.

An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period, and fasting glucose and insulin will also be measured at screening and at the first test visit in each treatment period. Fasting blood samples will be collected for lipid profile and high-sensitivity C-reactive protein (hs-CRP) measurements at all treatment visits. Additionally, fasting blood will be drawn for measurement of apolipoprotein B and A1 and lipoprotein particles and subfractions at baseline and the end of each treatment period.

Assessments of vital signs, body weight, evaluation of inclusion and exclusion criteria, medication/supplement use, and adverse effects will be performed throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: July 16, 2019
• Est. primary completion date: July 16, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. BMI of 25.0-39.9 kg/m2.

2. Metabolic syndrome (exhibiting at least 3 out of 5 of the criteria) AND/OR prediabetes (either fingerstick glycated hemoglobin 5.7-6.4%, fasting fingerstick capillary glucose of 100-125 mg/dL, or 2-h post-prandial glucose of 140-199 mg/dL).

3. Fasting LDL-C level <200 mg/dL and fasting TG level <400 mg/dL.

4. Willingness to consume only study-related foods/beverages during each test period and consume all of the study foods provided for each day.

5. Willingness to come to the clinic for study food pick-up as needed.

6. Judged to be in general good health, aside from the inclusionary metabolic criteria for the study, on the basis of medical history and screening laboratory tests.

Exclusion Criteria:

1. Atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound], history of myocardial infarction, angina, or other forms of clinical atherosclerotic disease (e.g., renal artery disease).

2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or type 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.

3. Known allergy, sensitivity, or intolerance to any ingredients in the study foods (e.g., dairy, nuts, etc.).

4. Uncontrolled hypertension.

5. Recent history of cancer except for non-melanoma skin cancer.

6. Recent change in body weight of ± 4.5 kg (10 lbs).

7. Unstable use of any antihypertensive medication.

8. Recent use of medications intended to alter the lipid profile [e.g., bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, and/or proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors], weight-loss drugs or programs, systemic corticosteroid drugs, medications known to influence carbohydrate metabolism (e.g., adrenergic receptor blockers, diuretics, and/or hypoglycemic medications).

9. Recent use of foods or dietary supplements known to influence lipid metabolism (e.g., omega-3 fatty acids supplements or fortified foods, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues at doses >400 mg/d and irregular or inconsistent use of Metamucil® or viscous fiber-containing supplements.

10. Recent use of antibiotics.

11. Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.

12. Extreme dietary habits (e.g., very low carbohydrate diet, vegan, vegetarian, etc.) or unwillingness to consume study foods.

13. Current or recent history or strong potential for drug or alcohol abuse.

14. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).

15. Recent exposure to any non-registered drug product.

Related Conditions & MeSH terms

• Insulin Resistance
• Metabolic Syndrome
• PreDiabetes
• Prediabetic State

Intervention

Other:
• USDA Style Diet
USDA style healthy diet, low in saturated fats.
• Lean Beef Diet
A lean beef containing healthy diet, low in saturated fats.

Locations

Country	Name	City	State
United States	MB Clinical Research, LLC	Boca Raton	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Midwest Center for Metabolic and Cardiovascular Research	National Cattlemen's Beef Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in insulin sensitivity index (Si)	Differences in the change from baseline between test conditions (lean beef diet and USDA diet) in the insulin sensitivity index (Si) using the short IVGTT.	Up to 50 minutes - measured at baseline, and end of each treatment period.
Secondary	Disposition index of pancreatic beta-cell function [Si x acute insulin response to intravenous glucose (AIRg)]	Percent change (or change) from baseline to the end of each test condition.	Up to 50 minutes - measured at baseline, and end of each treatment period.
Secondary	Fractional glucose disappearance constant from t = 10-50 min (Kg)	Percent change (or change) from baseline to the end of each test condition.	Up to 50 minutes - measured at baseline, and end of each treatment period.
Secondary	Homeostasis model assessment of beta cell function (HOMA%B) and insulin sensitivity (HOMA%S)	Percent change (or change) from baseline to the end of each test condition.	Up to 28 days for each treatment period.
Secondary	Insulin sensitivity (HOMA%S)	Percent change (or change) from baseline to the end of each test condition.	Up to 28 days for each treatment period.
Secondary	Total Cholesterol (TC)	Percent change (or change) in TC from baseline to the end of each test condition	Up to 28 days for each treatment period.
Secondary	Low-density Lipoprotein Cholesterol (LDL-C)	Percent change (or change) in LDL-C from baseline to the end of each test condition	Up to 28 days for each treatment period.
Secondary	High-density Lipoprotein Cholesterol (HDL-C)	Percent change (or change) in HDL-C from baseline to the end of each test condition	Up to 28 days for each treatment period.
Secondary	Non-HDL-C	Percent change (or change) in Non-HDL-C from baseline to the end of each test condition	Up to 28 days for each treatment period.
Secondary	Triglycerides (TG)	Percent change (or change) in TG from baseline to the end of each test condition	Up to 28 days for each treatment period.
Secondary	TC/HDL-C ratio	Percent change (or change) in TC/HDL-C ratio from baseline to the end of each test condition	Up to 28 days for each treatment period.
Secondary	High-sensitivity C-reactive protein (hs-CRP)	Percent change (or change) from baseline to the end of each test condition in levels of hs-CRP	Up to 28 days for each treatment period.
Secondary	Resting, seated systolic and diastolic blood pressures	Percent change (or change) from baseline to the end of each test condition.	Up to 28 days for each treatment period.
Secondary	Lipoprotein subfraction and particle concentrations.	Percent change (or change) in lipoprotein subfraction and particle concentrations from baseline to the end of each test condition.	Up to 28 days for each treatment period.
Secondary	Apo B measurements.	Percent change (or change) in Apo B levels from baseline to the end of each test condition.	Up to 28 days for each treatment period.
Secondary	Apo A1 measurements.	Percent change (or change) in Apo A1 levels from baseline to the end of each test condition.	Up to 28 days for each treatment period.